Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 11, 2012 - Issue 4
Submit an article Journal homepage
245
Views
5
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer

Geraldine O'Sullivan CoyneMater Misericordiae University Hospital, Department of Medical Oncology, Eccles St, Dublin 7, Ireland+353 1 8034839; +353 1 8034836; [email protected]
, MD PhD,
Janice WalsheSt Vincent's University Hospital, Department of Medical Oncology, Elm Park, Dublin 4, Ireland
, MB BCh &
Catherine M KellyMater Misericordiae University Hospital, Department of Medical Oncology, Eccles St, Dublin 7, Ireland+353 1 8034839; +353 1 8034836; [email protected]
, MD MSc (Clin.Epi)
Pages 643-650 | Published online: 14 Jun 2012

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Liang Xu, Xiaobo Wu, Chun Hu, Zhiying Zhang, Le Zhang, Shujing Liang, Yingchun Xu & Fengchun Zhang. (2016) A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials. OncoTargets and Therapy 9, pages 4061-4074.
Read now

Articles from other publishers (4)

Kaniz Afroz Tanni, Cong Bang Truong, Brandon S. Johnson & Jingjing Qian. (2021) Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 163, pages 103375.
Crossref
Bhuvic Patel, Rukayat Taiwo, Albert H Kim & Gavin P Dunn. (2020) TERT, a promoter of CNS malignancies. Neuro-Oncology Advances 2:1.
Crossref
Hirobumi Suzuki, Yoshihiro Hirata, Nobumi Suzuki, Sozaburo Ihara, Kosuke Sakitani, Yuka Kobayashi, Hiroto Kinoshita, Yoku Hayakawa, Atsuo Yamada, Hirotsugu Watabe, Keisuke Tateishi, Tsuneo Ikenoue, Yutaka Yamaji & Kazuhiko Koike. (2015) Characterization of a New Small Bowel Adenocarcinoma Cell Line and Screening of Anti-Cancer Drug against Small Bowel Adenocarcinoma. The American Journal of Pathology 185:2, pages 550-562.
Crossref
Claudio Scavelli & Federica Gallù. (2014) Long-term efficacy and safety of a third-line treatment with eribulin plus trastuzumab in a young breast cancer patient. Future Oncology 10:14, pages 2127-2132.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.